Evidence map›Paper›PMID 25875604›Full record

ArticlePLoS neglected tropical diseases2015

The B cell adaptor molecule Bam32 is critically important for optimal antibody response and resistance to Trypanosoma congolense infection in mice.

Chukwunonso Onyilagha, Ping Jia, Nipun Jayachandran, Sen Hou, Ifeoma Okwor, Shiby Kuriakose, Aaron Marshall, Jude E Uzonna

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Frontiers in microbiology · 2023
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. In-depth PtdIns(3,4,5)PBlood advances · 2017
    Article
  12. Unconventional Pro-inflammatory CD4Frontiers in immunology · 2017
    Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chukwunonso OnyilaghaDepartment of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Ping JiaDepartment of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Nipun JayachandranDepartment of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Sen HouDepartment of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Ifeoma OkworDepartment of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Shiby KuriakoseDepartment of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Aaron MarshallDepartment of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Jude E UzonnaDepartment of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
University of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBam32, a 32 kDa adaptor molecule, plays important role in B cell receptor signalling, T cell receptor signalling and antibody affinity maturation in germinal centres. Since antibodies against trypanosome variant surface glycoproteins (VSG) are critically important for control of parasitemia, we hypothesized that Bam32 deficient (Bam32-/-) mice would be susceptible to T. congolense infection. METHODOLOGY/PRINCIPAL

findingsWe found that T. congolense-infected Bam32-/- mice successfully control the first wave of parasitemia but then fail to control subsequent waves and ultimately succumb to their infection unlike wild type (WT) C57BL6 mice which are relatively resistant. Although infected Bam32-/- mice had significantly higher hepatomegaly and splenomegaly, their serum AST and ALT levels were not different, suggesting that increased liver pathology may not be responsible for the increased susceptibility of Bam32-/- mice to T. congolense. Using direct ex vivo flow cytometry and ELISA, we show that CD4+ T cells from infected Bam32-/- mice produced significantly increased amounts of disease-exacerbating proinflammatory cytokines (including IFN-γ, TNF-α and IL-6). However, the percentages of regulatory T cells and IL-10-producing CD4+ cells were similar in infected WT and Bam32-/- mice. While serum levels of parasite-specific IgM antibodies were normal, the levels of parasite-specific IgG, (particularly IgG1 and IgG2a) were significantly lower in Bam32-/- mice throughout infection. This was associated with impaired germinal centre response in Bam32-/- mice despite increased numbers of T follicular helper (Tfh) cells. Adoptive transfer studies indicate that intrinsic B cell defect was responsible for the enhanced susceptibility of Bam32-/- mice to T. congolense infection. CONCLUSIONS/SIGNIFICANCE: Collectively, our data show that Bam32 is important for optimal anti-trypanosome IgG antibody response and suppression of disease-promoting proinflammatory cytokines and its deficiency leads to inability to control T. congolense infection in mice.

Indexed as

Adaptor Proteins, Signal TransducingAdoptive TransferAnimalsAntibody AffinityAntibody FormationB-LymphocytesCytokinesDisease SusceptibilityImmunoglobulin GImmunoglobulin MLipoproteinsMiceMice, Inbred C57BLMice, KnockoutParasitemiaT-Lymphocytes, RegulatoryAdaptor Proteins, Signal TransducingCytokinesDapp1 protein, mouseImmunoglobulin GImmunoglobulin MLipoproteins

Identifiers

PMID25875604
PMCPMC4395458
OpenAlexW2011316585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.